Report overview
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
This report aims to provide a comprehensive presentation of the global market for RNA-Based Therapeutics and Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Based Therapeutics and Vaccines. This report contains market size and forecasts of RNA-Based Therapeutics and Vaccines in global, including the following market information:
Global RNA-Based Therapeutics and Vaccines Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global RNA-Based Therapeutics and Vaccines market was valued at US$ 26 million in 2022 and is projected to reach US$ 558.8 million by 2029, at a CAGR of 54.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
RNA-based biopharmaceuticals are a relatively new class of therapies that are demonstrating significant growth and potential for the treatment and prevention of chronic and rare diseases.
We surveyed the RNA-Based Therapeutics and Vaccines companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global RNA-Based Therapeutics and Vaccines Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global RNA-Based Therapeutics and Vaccines Market Segment Percentages, by Type, 2022 (%)
RNA-Based Therapeutics
RNA-Based Vaccines
Global RNA-Based Therapeutics and Vaccines Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global RNA-Based Therapeutics and Vaccines Market Segment Percentages, by Application, 2022 (%)
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Global RNA-Based Therapeutics and Vaccines Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global RNA-Based Therapeutics and Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies RNA-Based Therapeutics and Vaccines revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies RNA-Based Therapeutics and Vaccines revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Outline of Major Chapters:
Chapter 1: Introduces the definition of RNA-Based Therapeutics and Vaccines, market overview.
Chapter 2: Global RNA-Based Therapeutics and Vaccines market size in revenue.
Chapter 3: Detailed analysis of RNA-Based Therapeutics and Vaccines company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of RNA-Based Therapeutics and Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
